Leerink Maintains Outperform for Cytokinetics, Incorporated (CYTK) March 2026

Leerink Partners maintained Outperform on Cytokinetics, Incorporated (CYTK) on March 10, 2026. This note is a clear entry in the ongoing CYTK analyst rating record and follows a company conference. Leerink’s reiteration signals continued confidence in Cytokinetics’ mid‑stage programs, while the market reaction was muted with a 0.45% ($0.29) price move.